Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

20P - Quantitative whole slide assessment of CD8+ tumour-infiltrating lymphocytes in small cell esophageal carcinoma in relation to clinical outcome


09 Dec 2020


e-Poster Display Session


Zhihui Zhang


Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389


Z. Zhang1, C. Zhang2, G. Zhang2, L. Xue2, Q. Zeng1

Author affiliations

  • 1 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 2 Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing/CN

Abstract 20P


Primary small cell esophageal carcinoma (SCEC) represents a rapidly progressive, aggressive, and rare malignancy without any established treatment strategy. Given the great success of cancer immunotherapy targeting the PD-1/PD-L1 pathway in small cell lung cancer and the central role of CD8+ tumor-infiltrating lymphocytes (TIL) in the response to immune checkpoint inhibitors, we set out to assess the expression pattern and clinical significance of CD8+ TIL in SCESs for the first time.


Totally, 147 SCEC patients underwent surgery at our institution between 1985 and 2019 were collected. The formalin-fixed paraffin-embedded whole tumor sections were immunostained for CD8 with monoclonal mouse antibody. Whole-slide scanning was performed and the tumor regions were annotated by a trained gastrointestinal pathologist. The digital image analysis was then performed to quantify the CD8+ TILs density. Baseline clinicopathological features and outcome data (relapse free survival (RFS) and overall survival (OS)) were correlated with CD8+ TIL states.


The median number of CD8+ TIL cells in SCECs was 111.1 cells/mm2, with the range of 7.5 to 1458.6 cells/mm2. The mean destiny (195.9 cells/mm2) was used as cut-off value stratifying CD8+ TIL positive or negative groups. Positive CD8+ TILs infiltration was found significantly related to macroscopic tumor type (P=0.006), T stage (P=0.007) and TNM stage (P=0.005). Kaplan–Meier analysis showed that patients with positive CD8+ TILs state showed dramatically better RFS (HR = 0.456, 95% CI 0.309–0.674, P=0.0004) and OS (HR = 0.423, 95% CI 0.273–0.657, P=0.0008). Univariate and multivariate Cox regression analyses confirmed that CD8+ TIL state was the significant independent predictor for both RFS and OS, with P values of 0.0140 and 0.0457, respectively.


Here, for the first, we demonstrated that CD8+ TIL destiny was associated with an early stage and favorable clinical outcome in SCECs, supporting its role as a prognostic biomarker. These findings will not only help to improve risk-adapted therapeutic strategies, but also provide a rational basis for further investigation of PD-L1/PD-1-based immunotherapy for patients with SCECs.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.